The GreenGlia™ Platform

The nVector Platform – Next generation impact for CNS solutions

Gene therapy for CNS conditions promises great potential cures. But so far development has been slowed by lack of ability to target and access the right cells, and limited gene expression. Now, the nVector platform can help overcome those barriers.

More targeted — first platform to target glia (immune) and neuron cells by cell type.

Better distribution – throughout the spinal cord and brain from single injection.

More opportunity – 10 MM novel capsid library can support a wide array of CNS gene therapy initiatives.

Fast-Track Your Gene Therapy Projects with nVector’s AAV Platform

Whether you’re a big pharma company or a fast-growing life sciences startup looking to expedite clinical trials and acquisitions, we can support your journey.

We provide the tools and expertise to help you quickly launch your gene therapy initiatives by leveraging:

Existing AAV capsids with Enhanced Properties:

Utilize our proven technology to speed up development.

Our existing AAV (adeno-associated virus) capsids, including nCap-001, are engineered for superior performance, featuring improved diffusion and intracellular transport. This enhances their ability to deliver therapeutic genes effectively. These capsids have been validated in the primate CNS.

Existing Extensive Capsid Library:

Tap into our extensive resources to find suitable candidates.

Our GreenGlia® library includes over 10 million capsid variants aimed specifically at targeting glial cells, which are vital for brain health. Although focused on glia, this existing library can be queried for any cell type of interest.

Engineering novel AAV capsids

Collaborate with us to create customized solutions tailored to your specific requirements.

Targeted AAV technology: We offer a cutting-edge platform for designing novel AAVs capsids, including our unique nCap-001.

Innovative Design tools: We utilize advanced computational biology techniques to improve capsid design and development. This means we can rapidly identify and optimize AAVs that can target any cell type, making our platform versatile for various therapeutic needs.

Although our focus is on neurodegeneration and inflammation, our platform allows for the generation of novel AAVs that target specific cell types in the body

Therapeutic’s in Development

CavGene Inc. – CGT-102 and CGT-103: RNAi therapeutic targeting a voltage-gated L-type calcium channel (Cav1.3). Gene therapy to prevent or delay dyskinesias associated with Parkinson’s disease.
Kynura …………Place holder waiting for copy
nVector Inc. – nAV-101: Advancing the treatment of ALS.
nVector Inc.- nAV-102: Advance targeting for Huntington’s and Parkinson’s protocols.

Our Gene Therapy Expertise

Led by industry veterans, including Dr. Frederic Manfredsson , an acclaimed leader in Gene therapy research, and Dr. Ivette Sandoval head of vector development with over 30 years in gene therapy development, our team is dedicated to delivering precision in your gene therapy initiatives.

Biomarker Testing Accelerates Outcomes

We empower bioscience innovators by offering specialized biomarker testing services for central nervous system (CNS) disorders, including ALS, Huntington’s Disease, Parkinson’s Disease, Alzheimer’s Disease, and Traumatic Brain Injury. Our extensive experience spans preclinical through Phase III studies, enabling us to enhance your research outcomes through expert support in study protocols, trial design, and assay development.

Our Biomarker Expertise

Led by industry veterans, including Dr. Robert Bowser, an acclaimed leader in ALS research, and Jiyan An, our seasoned Lab Manager with over 30 years in biomarker testing and assay development, our team is dedicated to delivering precision and reliability in every study.

Comprehensive Testing Capabilities

Our laboratory is equipped to assess a wide array of neuroinflammatory, neurodegenerative, and neurobiological markers. We specialize in advanced assays, including but not limited to: